1. Home
  2. RDI vs VTGN Comparison

RDI vs VTGN Comparison

Compare RDI & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

HOLD

Current Price

$1.11

Market Cap

23.6M

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.61

Market Cap

21.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
VTGN
Founded
1937
1998
Country
United States
United States
Employees
2025
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.6M
21.8M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
RDI
VTGN
Price
$1.11
$0.61
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$0.90
AVG Volume (30 Days)
22.2K
736.7K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$124.49
Revenue Next Year
$13.42
$353.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.43
52 Week High
$1.65
$5.14

Technical Indicators

Market Signals
Indicator
RDI
VTGN
Relative Strength Index (RSI) 51.96 44.36
Support Level $1.07 $0.50
Resistance Level $1.16 $0.65
Average True Range (ATR) 0.06 0.04
MACD 0.01 0.02
Stochastic Oscillator 74.36 54.55

Price Performance

Historical Comparison
RDI
VTGN

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Share on Social Networks: